| Name | Title | Contact Details |
|---|
Small molecule protein degraders are set to reshape the way by which diseases will be treated. Our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. Headquartered in Boston with additional laboratory facilities in Basel, Monte Rosa Therapeutics is a private company launched in 2020. Initially seeded by Versant Ventures and incubated at Ridgeline Discovery in Basel, and The Institute of Cancer Research in London, Monte Rosa has raised $32.5 million from Versant and New Enterprise Associates. Academic co-founders are Prof. Raj Chopra and Prof. Ian Collins of The Institute for Cancer Research, UK.
Elevation Pharmaceuticals is a biopharmaceutical company focused on developing new inhaled therapies for patients with respiratory disease.
Arrowhead Pharmaceuticals is a clinical stage, Nasdaq listed (ticker ARWR) company developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, our therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Our RNAi-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. Our Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. The TRiM platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing and reduced costs; multiple routes of administration; and potential for improved safety. Our employees are nimble, science-driven, and innovative professionals. A career at Arrowhead offers the opportunity to collaborate with top notch scientists to rapidly discover and develop RNAi-based therapeutics to add to our growing pipeline. Research and development activities are located in Madison, WI. Our R&D group includes fully-integrated capabilities for chemistry, biology, and toxicology. Madison is an exciting and sophisticated city that includes state government, the flagship campus of the University of Wisconsin, and major research organizations. Our HQ, clinical and regulatory operations are located in Pasadena, CA. Just north of Los Angeles and resting in the foothills of the San Gabriel Mountains, Pasadena is known for its natural scenic beauty, vibrant cultural and academic environment and rich architectural setting.
Union Springs Pharmaceuticals is a Union, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Direct Pharmacy Service is a Lanham, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.